Previous 10 | Next 10 |
Dr. Reddy's has launched multiple drugs in the US market recently which are expected to drive significant growth. The launch of bortezomib drug to give the company access to $1.2 billion myeloma treatment market. I assign a Hold rating for RDY after taking into consideration all t...
Dr. Reddy's Laboratories Limited (RDY) Q1 2023 Earnings Conference Call July 28, 2022 9:00 A.M. ET Company Participants Amit Agarwal - Head of Investor Relations and Director of Finance Parag Agarwal - Chief Financial Officer Erez Israeli - Chief Executive Office...
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced that it has entered into a licensing agreement with Princeton, New Jersey based Slayback ...
Dr. Reddy's press release ( NYSE: RDY ): Q1 GAAP EPS of $0.90. Revenue of $660M (+5.9% Y/Y) misses by $12.78M . For further details see: Dr. Reddy's GAAP EPS of $0.90, revenue of $660M misses by $12.78M
Dr. Reddy's ( NYSE: RDY ) is scheduled to announce Q1 earnings results on Thursday, July 28th, before market open. The consensus EPS Estimate is $0.52 (vs. $0.46 last year) and the consensus Revenue Estimate is $673.07M (+1.7% Y/Y). Over the last 3 months, EPS estimate...
Dr. Reddy’s Laboratories ( NYSE: RDY ) launched a generic version of Takeda Pharmaceutical's ( NYSE: TAK ) multiple myeloma therapy Velcade in the U.S. market. The Indian generic drugmaker said that its drug bortezomib for Injection 3.5-mg...
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the launch of Bortezomib for Injection 3.5 mg, the generic equivalent of Velcade® (b...
Dr. Reddy's Laboratories Ltd. ( NYSE: RDY ) announced the first-to-market launch of over-the-counter (OTC) fexofenadine HCl 180 mg and pseudoephedrine HCl 240 mg extended release tablets, the store-brand equivalent of Allegra-D 24 HR in the U.S. market. The company sai...
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) today announced the first-to-market launch of over-the-counter (OTC) Fexofenadine HCl 180 mg and Pseudoep...
Dr. Reddy’s Laboratories Ltd. (BSE: 500124, NSE: DRREDDY, NYSE: RDY, NSEIFSC: DRREDDY, along with its subsidiaries together referred to as “Dr. Reddy’s”) announces the launch of Dr. Reddy’s Fesoterodine Fumarate Extended-Release Tablets, a therapeutic ...
News, Short Squeeze, Breakout and More Instantly...
Dr. Reddy's Laboratories Ltd Company Name:
RDY Stock Symbol:
NYSE Market:
Dr. Reddy's Laboratories Ltd Website:
2024-07-04 03:56:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...
Portfolio to be acquired consists of global NRT brand Nicotinell and its local market-leading brand names Nicabate, Habitrol and Thrive in markets outside of the United States Acquisition seen as ideal anchor to continue to build the company’s global consumer healthcare OTC busines...
Aurigene Pharmaceutical Services Limited (“Aurigene”), a Dr. Reddy’s Laboratories Limited company, inaugurated its biologics facility spread across 70,000 sq.ft. in Genome Valley, a bio cluster, located in Hyderabad, India. The facility is designed to serve customers with pro...